KR20030069216A - 히스타민 수용체 길항제 - Google Patents

히스타민 수용체 길항제 Download PDF

Info

Publication number: KR20030069216A
Authority: KR; South Korea
Prior art keywords: histamine; receptor; antagonist; asthma; antagonists
Prior art date: 2001-01-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

KR10-2003-7009493A

Other languages

English (en)

Korean (ko)

Inventor

젠킨슨스티븐

오레일리마크앤터니

트레베씨크마이클앤드류

Original Assignee

화이자 인코포레이티드

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-17

Filing date

2002-01-10

Publication date

2003-08-25

2002-01-10 Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드

2003-08-25 Publication of KR20030069216A publication Critical patent/KR20030069216A/ko

Status Ceased legal-status Critical Current

Links

229940122236 Histamine receptor antagonist Drugs 0.000 title 1
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims abstract description 174
229960001340 histamine Drugs 0.000 claims abstract description 87
239000000203 mixture Substances 0.000 claims abstract description 62
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
208000006673 asthma Diseases 0.000 claims abstract description 25
201000010099 disease Diseases 0.000 claims abstract description 23
208000035475 disorder Diseases 0.000 claims abstract description 22
238000011282 treatment Methods 0.000 claims abstract description 22
206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 21
201000010105 allergic rhinitis Diseases 0.000 claims abstract description 21
230000008485 antagonism Effects 0.000 claims abstract description 16
201000009961 allergic asthma Diseases 0.000 claims abstract description 14
238000000034 method Methods 0.000 claims abstract description 14
238000009472 formulation Methods 0.000 claims abstract description 10
239000005557 antagonist Substances 0.000 claims description 62
239000000938 histamine H1 antagonist Substances 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 14
241000124008 Mammalia Species 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
239000003085 diluting agent Substances 0.000 claims description 5
239000000969 carrier Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
239000003396 histamine H4 receptor antagonist Substances 0.000 abstract description 16
208000026935 allergic disease Diseases 0.000 abstract description 5
-1 their use Substances 0.000 abstract description 5
229940044551 receptor antagonist Drugs 0.000 abstract description 3
239000002464 receptor antagonist Substances 0.000 abstract description 3
102000005962 receptors Human genes 0.000 description 59
108020003175 receptors Proteins 0.000 description 59
210000003979 eosinophil Anatomy 0.000 description 20
229920001184 polypeptide Polymers 0.000 description 12
102000004196 processed proteins & peptides Human genes 0.000 description 12
108090000765 processed proteins & peptides Proteins 0.000 description 12
230000035605 chemotaxis Effects 0.000 description 10
230000000694 effects Effects 0.000 description 10
208000024891 symptom Diseases 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
230000000172 allergic effect Effects 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
150000001875 compounds Chemical class 0.000 description 8
206010028735 Nasal congestion Diseases 0.000 description 7
208000010668 atopic eczema Diseases 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
229920000858 Cyclodextrin Polymers 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000000556 agonist Substances 0.000 description 6
239000003446 ligand Substances 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
QKDDJDBFONZGBW-UHFFFAOYSA-N N-Cyclohexy-4-(imidazol-4-yl)-1-piperidinecarbothioamide Chemical compound C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 QKDDJDBFONZGBW-UHFFFAOYSA-N 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
239000003395 histamine H3 receptor antagonist Substances 0.000 description 4
230000008595 infiltration Effects 0.000 description 4
238000001764 infiltration Methods 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
241000244206 Nematoda Species 0.000 description 3
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000001684 chronic effect Effects 0.000 description 3
UCAIEVHKDLMIFL-UHFFFAOYSA-N clobenpropit Chemical compound C1=CC(Cl)=CC=C1CNC(=N)SCCCC1=CNC=N1 UCAIEVHKDLMIFL-UHFFFAOYSA-N 0.000 description 3
229940095074 cyclic amp Drugs 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
208000026278 immune system disease Diseases 0.000 description 3
208000027866 inflammatory disease Diseases 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000002674 ointment Substances 0.000 description 3
235000019271 petrolatum Nutrition 0.000 description 3
206010039083 rhinitis Diseases 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
208000035473 Communicable disease Diseases 0.000 description 2
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010014950 Eosinophilia Diseases 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
102000030782 GTP binding Human genes 0.000 description 2
108091000058 GTP-Binding Proteins 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
206010018691 Granuloma Diseases 0.000 description 2
102100032511 Histamine H4 receptor Human genes 0.000 description 2
101001016858 Homo sapiens Histamine H4 receptor Proteins 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
102000000743 Interleukin-5 Human genes 0.000 description 2
108010002616 Interleukin-5 Proteins 0.000 description 2
208000014767 Myeloproliferative disease Diseases 0.000 description 2
239000004264 Petrolatum Substances 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
229940097362 cyclodextrins Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229960002017 echothiophate Drugs 0.000 description 2
BJOLKYGKSZKIGU-UHFFFAOYSA-N ecothiopate Chemical compound CCOP(=O)(OCC)SCC[N+](C)(C)C BJOLKYGKSZKIGU-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
229940100602 interleukin-5 Drugs 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000007794 irritation Effects 0.000 description 2
239000006210 lotion Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
230000004199 lung function Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000005012 migration Effects 0.000 description 2
238000013508 migration Methods 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940066842 petrolatum Drugs 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000003380 propellant Substances 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
230000001932 seasonal effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
239000007916 tablet composition Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
ODAOZWTYNWZSBY-SPIKMXEPSA-N (z)-but-2-enedioic acid;6-[2-(1h-imidazol-5-yl)ethylamino]-n-[4-(trifluoromethyl)phenyl]heptanamide Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1N=CNC=1CCNC(C)CCCCC(=O)NC1=CC=C(C(F)(F)F)C=C1 ODAOZWTYNWZSBY-SPIKMXEPSA-N 0.000 description 1
WUYMIKDBRCCYGE-BTJKTKAUSA-N (z)-but-2-enedioic acid;n-cyclohexyl-4-(1h-imidazol-5-yl)piperidine-1-carbothioamide Chemical compound OC(=O)\C=C/C(O)=O.C1CC(C=2NC=NC=2)CCN1C(=S)NC1CCCCC1 WUYMIKDBRCCYGE-BTJKTKAUSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241000238876 Acari Species 0.000 description 1
206010027654 Allergic conditions Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
208000003732 Cat-scratch disease Diseases 0.000 description 1
208000000362 Chlamydial Pneumonia Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
208000015943 Coeliac disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
108090000204 Dipeptidase 1 Proteins 0.000 description 1
241000239183 Filaria Species 0.000 description 1
208000036119 Frailty Diseases 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010062639 Herpes dermatitis Diseases 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
208000016300 Idiopathic chronic eosinophilic pneumonia Diseases 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
UBHYDQAARZKHEZ-UHFFFAOYSA-N N'-[2-(4-iodophenyl)ethyl]carbamimidothioic acid 3-(1H-imidazol-5-yl)propyl ester Chemical compound C=1C=C(I)C=CC=1CCN=C(N)SCCCC1=CN=CN1 UBHYDQAARZKHEZ-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
206010051246 Photodermatosis Diseases 0.000 description 1
208000002151 Pleural effusion Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010035673 Pneumonia chlamydial Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
206010039101 Rhinorrhoea Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000000150 Sympathomimetic Substances 0.000 description 1
206010042971 T-cell lymphoma Diseases 0.000 description 1
208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000025609 Urogenital disease Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001467 acupuncture Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
239000000808 adrenergic beta-agonist Substances 0.000 description 1
208000026802 afebrile Diseases 0.000 description 1
208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
206010003230 arteritis Diseases 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000006635 beta-lactamase Human genes 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940081733 cetearyl alcohol Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
201000009323 chronic eosinophilic pneumonia Diseases 0.000 description 1
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
229960001380 cimetidine Drugs 0.000 description 1
238000000576 coating method Methods 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
239000007933 dermal patch Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
OLHQOJYVQUNWPL-UHFFFAOYSA-N dimaprit Chemical compound CN(C)CCCSC(N)=N OLHQOJYVQUNWPL-UHFFFAOYSA-N 0.000 description 1
238000007907 direct compression Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000000138 effect on histamine Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000008387 emulsifying waxe Substances 0.000 description 1
230000013764 eosinophil chemotaxis Effects 0.000 description 1
239000003172 expectorant agent Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
230000005714 functional activity Effects 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229940049654 glyceryl behenate Drugs 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
208000020390 granulomatous prostatitis Diseases 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
230000035876 healing Effects 0.000 description 1
201000008298 histiocytosis Diseases 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
PEHSVUKQDJULKE-UHFFFAOYSA-N imetit Chemical compound NC(=N)SCCC1=CNC=N1 PEHSVUKQDJULKE-UHFFFAOYSA-N 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000036971 interstitial lung disease 2 Diseases 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007914 intraventricular administration Methods 0.000 description 1
229940090504 iodopen Drugs 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940066491 mucolytics Drugs 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
230000000414 obstructive effect Effects 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
229960000395 phenylpropanolamine Drugs 0.000 description 1
230000008845 photoaging Effects 0.000 description 1
208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
201000007094 prostatitis Diseases 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
229960003908 pseudoephedrine Drugs 0.000 description 1
238000001671 psychotherapy Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
210000000697 sensory organ Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000001587 sorbitan monostearate Substances 0.000 description 1
235000011076 sorbitan monostearate Nutrition 0.000 description 1
229940035048 sorbitan monostearate Drugs 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940071117 starch glycolate Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000001975 sympathomimetic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000017423 tissue regeneration Effects 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
201000007363 trachea carcinoma Diseases 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000982 vasogenic effect Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
238000005550 wet granulation Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Immunology (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

KR10-2003-7009493A 2001-01-17 2002-01-10 히스타민 수용체 길항제 Ceased KR20030069216A (ko)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0101223.6A GB0101223D0 (en)	2001-01-17	2001-01-17	Histamine receptor antagonists
GB0101223.6		2001-01-17
PCT/IB2002/000042 WO2002056871A2 (en)	2001-01-17	2002-01-10	Histamine receptor antagonists

Publications (1)

Publication Number	Publication Date
KR20030069216A true KR20030069216A (ko)	2003-08-25

Family

ID=9906993

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
KR10-2003-7009493A Ceased KR20030069216A (ko)	2001-01-17	2002-01-10	히스타민 수용체 길항제

Country Status (31)

Country	Link
EP (1)	EP1353657A1 (es)
JP (1)	JP2004517883A (es)
KR (1)	KR20030069216A (es)
CN (1)	CN1486178A (es)
AP (1)	AP2002002401A0 (es)
AR (1)	AR032101A1 (es)
BG (1)	BG107834A (es)
BR (1)	BR0206502A (es)
CA (1)	CA2435121A1 (es)
CR (1)	CR6983A (es)
CZ (1)	CZ20031853A3 (es)
DO (1)	DOP2002000325A (es)
EA (1)	EA200300537A1 (es)
EC (1)	ECSP034692A (es)
EE (1)	EE200300335A (es)
GB (1)	GB0101223D0 (es)
GT (1)	GT200200003A (es)
HU (1)	HUP0302767A2 (es)
IL (1)	IL156087A0 (es)
IS (1)	IS6818A (es)
MA (1)	MA26980A1 (es)
MX (1)	MXPA03006408A (es)
NO (1)	NO20033223L (es)
OA (1)	OA12440A (es)
PA (1)	PA8537101A1 (es)
PL (1)	PL362793A1 (es)
SK (1)	SK8572003A3 (es)
SV (1)	SV2003000849A (es)
TN (1)	TNSN02003A1 (es)
WO (1)	WO2002056871A2 (es)
ZA (1)	ZA200304180B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030133931A1 (en) *	2001-12-21	2003-07-17	Robin Thurmond	Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
WO2004021999A2 (en) *	2002-09-06	2004-03-18	Janssen Pharmaceutica, N.V.	Use of histamine h4 receptor modulators for the treatment of allergy and asthma
US20050090527A1 (en) *	2003-01-28	2005-04-28	Schering Corporation	Combination of H1, H3 and H4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis
US8236786B2 (en)	2008-08-07	2012-08-07	Pulmagen Therapeutics (Inflammation) Limited	Respiratory disease treatment
WO2013151982A1 (en)	2012-04-03	2013-10-10	Arena Pharmaceuticals, Inc.	Methods and compounds useful in treating pruritus, and methods for identifying such compounds
SI2858647T1 (sl)	2012-06-08	2018-11-30	Sensorion	Inhibitorji receptorja H4 za zdravljenje tinitusa
CN119823227B (zh) *	2025-01-14	2025-07-04	广州迪卡德营养科技有限公司	一种益生菌的制备方法及其在治疗过敏性鼻炎中的用途

2001
- 2001-01-17 GB GBGB0101223.6A patent/GB0101223D0/en not_active Ceased
2002
- 2002-01-10 CN CNA028036840A patent/CN1486178A/zh active Pending
- 2002-01-10 JP JP2002557379A patent/JP2004517883A/ja not_active Withdrawn
- 2002-01-10 BR BR0206502-9A patent/BR0206502A/pt not_active IP Right Cessation
- 2002-01-10 PL PL02362793A patent/PL362793A1/xx not_active Application Discontinuation
- 2002-01-10 IL IL15608702A patent/IL156087A0/xx unknown
- 2002-01-10 HU HU0302767A patent/HUP0302767A2/hu unknown
- 2002-01-10 EP EP02732099A patent/EP1353657A1/en not_active Withdrawn
- 2002-01-10 CZ CZ20031853A patent/CZ20031853A3/cs unknown
- 2002-01-10 SK SK857-2003A patent/SK8572003A3/sk unknown
- 2002-01-10 EA EA200300537A patent/EA200300537A1/ru unknown
- 2002-01-10 CA CA002435121A patent/CA2435121A1/en not_active Abandoned
- 2002-01-10 OA OA1200300174A patent/OA12440A/en unknown
- 2002-01-10 WO PCT/IB2002/000042 patent/WO2002056871A2/en not_active Ceased
- 2002-01-10 MX MXPA03006408A patent/MXPA03006408A/es unknown
- 2002-01-10 EE EEP200300335A patent/EE200300335A/xx unknown
- 2002-01-10 KR KR10-2003-7009493A patent/KR20030069216A/ko not_active Ceased
- 2002-01-11 DO DO2002000325A patent/DOP2002000325A/es unknown
- 2002-01-14 PA PA20028537101A patent/PA8537101A1/es unknown
- 2002-01-16 GT GT200200003A patent/GT200200003A/es unknown
- 2002-01-16 AR ARP020100145A patent/AR032101A1/es not_active Application Discontinuation
- 2002-01-16 TN TNTNSN02003A patent/TNSN02003A1/fr unknown
- 2002-01-16 SV SV2002000849A patent/SV2003000849A/es not_active Application Discontinuation
- 2002-01-17 AP APAP/P/2002/002401A patent/AP2002002401A0/en unknown
2003
- 2003-05-15 IS IS6818A patent/IS6818A/is unknown
- 2003-05-21 BG BG107834A patent/BG107834A/bg unknown
- 2003-05-22 CR CR6983A patent/CR6983A/es not_active Application Discontinuation
- 2003-05-29 ZA ZA200304180A patent/ZA200304180B/en unknown
- 2003-07-11 MA MA27233A patent/MA26980A1/fr unknown
- 2003-07-16 NO NO20033223A patent/NO20033223L/no not_active Application Discontinuation
- 2003-07-17 EC EC2003004692A patent/ECSP034692A/es unknown

Also Published As

Publication number	Publication date
NO20033223D0 (no)	2003-07-16
GT200200003A (es)	2002-08-19
BR0206502A (pt)	2003-10-21
EE200300335A (et)	2003-12-15
IL156087A0 (en)	2003-12-23
WO2002056871A2 (en)	2002-07-25
JP2004517883A (ja)	2004-06-17
CN1486178A (zh)	2004-03-31
SK8572003A3 (en)	2004-07-07
EA200300537A1 (ru)	2004-02-26
ZA200304180B (en)	2004-06-15
TNSN02003A1 (fr)	2005-12-23
CR6983A (es)	2003-11-25
BG107834A (bg)	2004-01-30
MXPA03006408A (es)	2003-10-15
CA2435121A1 (en)	2002-07-25
ECSP034692A (es)	2003-08-29
SV2003000849A (es)	2003-01-13
IS6818A (is)	2003-05-15
DOP2002000325A (es)	2003-01-31
CZ20031853A3 (cs)	2004-07-14
EP1353657A1 (en)	2003-10-22
AR032101A1 (es)	2003-10-22
AP2002002401A0 (en)	2002-03-31
HUP0302767A2 (hu)	2003-11-28
NO20033223L (no)	2003-07-16
OA12440A (en)	2006-05-22
GB0101223D0 (en)	2001-02-28
PA8537101A1 (es)	2002-08-29
MA26980A1 (fr)	2004-12-20
PL362793A1 (en)	2004-11-02

Publication	Publication Date	Title
EP1617832B1 (en)	2008-03-12	Compositions for affecting weight loss
TWI314054B (en)	2009-09-01	Novel methods and compositions for alleviating pain
TWI353835B (en)	2011-12-11	Novel methods for identifying improved, non-sedati
JP2003525240A (ja)	2003-08-26	糖尿病性腎障害の処置のためのｐｄｇｆ受容体チロシンキナーゼ阻害剤の使用
KR20070036079A (ko)	2007-04-02	성기능 장애에 관한 다중 제제 요법
US20210213001A1 (en)	2021-07-15	Method of treating a sleep breathing disorder
KR20030069216A (ko)	2003-08-25	히스타민 수용체 길항제
EP3923938B1 (en)	2025-04-16	Ifenprodil or radiprodil for treating idiopathic pulmonary fibrosis
EP1387685B1 (en)	2010-04-21	Analgesic composition comprising an opioid and a sodium channel blocker
KR20060004959A (ko)	2006-01-16	신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
CA2398261A1 (en)	2001-08-09	Treating allergic and inflammatory conditions
KR20050106038A (ko)	2005-11-08	심장질환 및 신장질환의 치료를 위한 아데노신 ａ1 수용체길항제
JP2003511410A (ja)	2003-03-25	肥満症の治療のためのモルホリノール誘導体
Crosson et al.	1999	Contributions of adenosine receptor activation to the ocular actions of epinephrine
EP2227235B1 (en)	2014-11-12	Mequitazine for treating or preventing obstructive bronchopneumopaty involving histamine h4 receptors
US20040138234A1 (en)	2004-07-15	Histamine receptor antagonists
Kabir et al.	2015	Different approaches in the treatment of obstructive pulmonary diseases
WO2006124506A2 (en)	2006-11-23	Combination and use of drugs
Dobrek et al.	2011	Current management and future perspectives of overactive bladder (OAB) pharmacotherapy
HK1060300A (en)	2004-08-06	Histamine receptor antagonists
AU2002216328A1 (en)	2002-07-30	Histamine receptor antagonists
JP4243701B2 (ja)	2009-03-25	ベンズアミド誘導体を有効成分とするリウマチ治療薬
JPWO2000012091A1 (ja)	2001-11-06	脊柱管狭窄症治療剤
EP1374870A1 (en)	2004-01-02	Medication for the treatment or prevention of migraine
WO2018197638A1 (en)	2018-11-01	Novel use of (5r)-5-[5-[{2-[3,5-bis(trifluoromethyl)phenyl]-2-methylpropanoyl}(methyl)amino]-4-(4-fluoro-2-methylphenyl)-2-pyridinyl]-2-methyl-d-prolinamide

Legal Events

Date	Code	Title	Description
2003-07-16	A201	Request for examination
2003-07-16	PA0105	International application	Patent event date: 20030716 Patent event code: PA01051R01D Comment text: International Patent Application
2003-07-16	PA0201	Request for examination	Patent event code: PA02012R01D Patent event date: 20030716 Comment text: Request for Examination of Application
2003-08-25	PG1501	Laying open of application
2005-04-27	E902	Notification of reason for refusal
2005-04-27	PE0902	Notice of grounds for rejection	Comment text: Notification of reason for refusal Patent event date: 20050427 Patent event code: PE09021S01D
2005-10-07	E601	Decision to refuse application
2005-10-07	PE0601	Decision on rejection of patent	Patent event date: 20051007 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20050427 Comment text: Notification of reason for refusal Patent event code: PE06011S01I